# US 2026/0227414 A1 · Isolation of podocytes from samples

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0227414 A1
- Document ID: US20260227414A1
- Status: Published application
- Kind: A1
- Application number: 19/154,737
- Filed: 2024-02-09
- Published: 2026-08-06
- Earliest claimed: 2023-02-09
- Assignees: Savran Technologies, Inc.
- Applicants: Savran Technologies, Inc.
- Inventors: Yuan Zhong; Edward Francis Boumil
- Web page: https://patentgrep.com/patent/US20260227414A1

## CPC

- C12N 5/0684: {Cells of the urinary tract or kidneys}
- G01N 33/689: {related to pregnancy or the gonads}
- A61B 5/4343: {Pregnancy and labour monitoring, e.g. for labour onset detection}
- A61B 10/007: {for taking urine samples (measuring urological functions A61B5/20; genital receptacles A61F5/451; urinals for bed-ridden persons A61G9/006)}
- C12N 5/0075: {using microcarriers}
- G01N 1/30: Staining; Impregnating {; Fixation; Dehydration; Multistep processes for preparing samples of tissue, cell or nucleic acid material and the like for analysis}
- G01N 1/34: Purifying; Cleaning {(processes or apparatus for extracting or separating nucleic acids from biological samples C12N15/1003)}
- G01N 33/54326: {Magnetic particles}
- A61B 5/201: {Assessing renal or kidney functions}
- G01N 2800/368: Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D)

## Abstract

The disclosure relates to methods of isolating podocytes from biological samples such as urine and methods of determining a risk of a pregnant woman developing preeclampsia during the pregnancy. In some embodiments, the disclosure provides methods of isolating podocytes from a biological sample; adding a plurality of antibodies to the biological sample; incubating the biological sample for a time and under conditions sufficient for the antibodies to bind to any podocytes in the biological sample; adding to the biological sample a plurality of magnetic beads; and flowing the biological sample containing the plurality of magnetic beads through a microfluidic chamber within a system that applies a magnetic force in a sufficiently perpendicular direction to the flow to attract the bead-bound podocytes onto a surface of a microchip present in the fluidic chamber.

## Claims

### Claim 1

A method of isolating podocytes from a biological sample from a pregnant woman, the method comprising
obtaining a mixture of magnetic beads and one or more different types of antibodies, wherein each of the types of antibodies bind specifically to podocytes, and wherein at least some of the magnetic beads are bound to at least one of the types of antibodies in the mixture, with each of the bound magnetic beads being bound to at least one of the antibodies;
combining the mixture of magnetic beads and antibodies with the biological sample from a pregnant woman to form a liquid sample, and incubating the liquid sample for a time and under conditions sufficient for the antibodies to bind to any podocytes that may be present in the biological sample to form podocyte-antibody-magnetic bead complexes; and
flowing the liquid sample containing podocyte-antibody-magnetic bead complexes, if any, through a microfluidic channel within a system that applies a magnetic force in a direction generally perpendicular to a direction of flow of the liquid sample with a magnetic field strength sufficient to attract the podocyte-antibody-magnetic bead complexes onto a surface of a microchip present in the fluidic chamber, and flowing remaining liquid sample out of the microfluidic channel, thereby isolating the podocytes from the biological sample.

### Claim 2 (depends on 1)

The method of claim 1, wherein the antibodies are bound to a first binding partner of a binding pair, and the magnetic beads are bound to a second binding partner of the binding pair, wherein the antibodies are bound to the magnetic beads when the first binding partner binds to the second binding partner.

### Claim 3 (depends on 1)

The method of claim 1, wherein the antibodies are bound to the magnetic beads or to a first binding partner via a linker molecule.

### Claim 4 (depends on 3)

The method of claim 3, wherein the linker molecule comprises polyethylene glycol (PEG).

### Claim 5 (depends on 3)

The method of claim 3, wherein the linker molecule has a molecular weight of about 5 kDa to 50 kDa.

### Claim 6 (depends on 1)

The method of claim 1, wherein the antibodies bind specifically to podocin, podoplanin, or podocalyxin.

### Claim 7 (depends on 6)

The method of claim 6, wherein the mixture of magnetic beads and antibodies comprises a first set of magnetic beads that are bound to anti-podocin antibodies, a second set of magnetic beads bound to anti-podoplanin antibodies, and a third set of magnetic beans bound to anti-podocalyxin antibodies.

### Claim 8 (depends on 1)

The method of claim 1, wherein the biological sample is urine from a pregnant woman.

### Claim 9 (depends on 1)

The method of claim 1, wherein the microchip comprises through holes or microwells with a through hole, wherein the through holes are smaller in diameter than podocytes, but larger than the magnetic beads, to enable excess magnetic beads to be cleared from the surface of the chip.

### Claim 10

(canceled)

### Claim 11 (depends on 1)

The method of claim 1, further comprising identifying which cells on the microchip are podocytes.

### Claim at position 12

12-13. (canceled)

### Claim 14 (depends on 11)

The method of claim 11, wherein identifying which cells on the microchip are podocytes comprises any one or more of:
positive staining of cells using a reporter group bound to an antibody that binds specifically to a podocyte-specific marker;
negative staining of cells using a reporter group bound to an antibody that specifically binds to a white blood cell marker; and
nuclear staining using a stain to label a nucleic acid.

### Claim 15 (depends on 14)

The method of claim 14, comprising the use of positive staining, negative staining, and nuclear staining.

### Claim 16

(canceled)

### Claim 17 (depends on 14)

The method of claim 14, wherein cells that are positive for synaptopodin and DAPI and negative for CD45 are counted as podocytes.

### Claim 18 (depends on 17)

The method of claim 17, wherein a presence of 3 podocytes/10 mL urine indicates a possibility that the pregnant woman may have or may develop preeclampsia during the pregnancy.

### Claim 19 (depends on 17)

The method of claim 17, wherein a presence of 5 podocytes/10 mL urine indicates that the pregnant woman has or will develop preeclampsia during the pregnancy.

### Claim at position 19

20-21. (canceled)

### Claim 22 (depends on 1)

The method of claim 1, further comprising analyzing the isolated podocytes, by qPCR, RT-qPCR, ddPCR, next-generation sequencing (NGS), or Western blotting.

### Claim 23

(canceled)

### Claim 24

A method of determining a risk of a pregnant woman developing preeclampsia, the method comprising
obtaining a biological sample that may contain podocytes from a pregnant woman; and
counting podocytes in a specific volume of the biological sample,
wherein a number of podocytes above a threshold level indicates a possible risk that the pregnant woman may have or may develop preeclampsia during the pregnancy.

### Claim 25 (depends on 24)

The method of claim 24, wherein the biological sample is urine, and wherein the threshold level is 3 podocytes/10 mL urine.

### Claim 26

(canceled)

### Claim 27 (depends on 24)

The method of claim 24, wherein the threshold level is set at 5 podocytes/10 mL urine, and wherein this threshold level indicates a high likelihood that the pregnant patient already has or will develop preeclampsia during the pregnancy.

### Claim 28 (depends on 24)

The method of claim 24, wherein the biological sample is obtained at or before about 20 weeks of gestational age.

### Claim 29

(canceled)
